JP2014508175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508175A5 JP2014508175A5 JP2013558200A JP2013558200A JP2014508175A5 JP 2014508175 A5 JP2014508175 A5 JP 2014508175A5 JP 2013558200 A JP2013558200 A JP 2013558200A JP 2013558200 A JP2013558200 A JP 2013558200A JP 2014508175 A5 JP2014508175 A5 JP 2014508175A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- alkyl
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000028017 Psychotic disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 5
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000013200 Stress disease Diseases 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000024714 major depressive disease Diseases 0.000 claims description 4
- 230000004584 weight gain Effects 0.000 claims description 4
- 235000019786 weight gain Nutrition 0.000 claims description 4
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- 206010012218 Delirium Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 206010017076 Fracture Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000021017 Weight Gain Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 231100000876 cognitive deterioration Toxicity 0.000 claims description 2
- 230000037410 cognitive enhancement Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 230000007365 immunoregulation Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 230000036457 multidrug resistance Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 208000021011 postpartum psychosis Diseases 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 238000000034 method Methods 0.000 description 9
- 0 *N(C(C(Cc1ccccc1)=C(C(CC1)CCC1c1ccccc1)N1)=O)C1=O Chemical compound *N(C(C(Cc1ccccc1)=C(C(CC1)CCC1c1ccccc1)N1)=O)C1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454289P | 2011-03-18 | 2011-03-18 | |
| US61/454,289 | 2011-03-18 | ||
| PCT/US2012/029376 WO2012129074A1 (en) | 2011-03-18 | 2012-03-16 | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014508175A JP2014508175A (ja) | 2014-04-03 |
| JP2014508175A5 true JP2014508175A5 (enExample) | 2015-03-19 |
| JP6039587B2 JP6039587B2 (ja) | 2016-12-07 |
Family
ID=46879684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558200A Active JP6039587B2 (ja) | 2011-03-18 | 2012-03-16 | ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8685973B2 (enExample) |
| EP (1) | EP2685827B1 (enExample) |
| JP (1) | JP6039587B2 (enExample) |
| KR (2) | KR101925955B1 (enExample) |
| CN (1) | CN103596431B (enExample) |
| AU (1) | AU2012231265B2 (enExample) |
| BR (1) | BR112013023689B1 (enExample) |
| CA (1) | CA2830411C (enExample) |
| CL (1) | CL2013002667A1 (enExample) |
| CO (1) | CO6821943A2 (enExample) |
| DK (1) | DK2685827T3 (enExample) |
| ES (1) | ES2563444T3 (enExample) |
| IL (1) | IL228466A (enExample) |
| MX (1) | MX347862B (enExample) |
| MY (1) | MY161170A (enExample) |
| PE (1) | PE20141378A1 (enExample) |
| PH (1) | PH12013501906A1 (enExample) |
| PL (1) | PL2685827T3 (enExample) |
| RU (1) | RU2599253C2 (enExample) |
| SG (1) | SG193509A1 (enExample) |
| UA (1) | UA109931C2 (enExample) |
| WO (1) | WO2012129074A1 (enExample) |
| ZA (1) | ZA201307245B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG193509A1 (en) * | 2011-03-18 | 2013-10-30 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US10183949B2 (en) | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
| ES2978871T3 (es) * | 2014-10-15 | 2024-09-23 | Corcept Therapeutics Inc | Tratamiento de la esteatosis hepática usando antagonistas de los receptores de glucocorticoides y de mineralocorticoides |
| CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| MX383353B (es) * | 2015-03-30 | 2025-03-13 | Corcept Therapeutics Inc | Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal. |
| MX383318B (es) | 2015-08-13 | 2025-03-13 | Corcept Therapeutics Inc | Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina. |
| JP6749399B2 (ja) * | 2015-09-15 | 2020-09-02 | レオ ファーマ アクティーゼルスカブ | 局所薬物送達のための非ステロイド性グルココルチコイド受容体モジュレーター |
| EP3405101B1 (en) | 2016-01-19 | 2020-12-23 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
| WO2018165460A1 (en) | 2017-03-09 | 2018-09-13 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| MX2019011543A (es) | 2017-03-31 | 2019-12-16 | Corcept Therapeutics Inc | Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical. |
| MX393313B (es) * | 2017-06-20 | 2025-03-24 | Corcept Therapeutics Inc | Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide. |
| AU2019282047B2 (en) * | 2018-06-04 | 2022-06-02 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| IL284061B2 (en) | 2018-12-19 | 2025-02-01 | Corcept Therapeutics Inc | A preparation containing a relaxant |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2021119432A1 (en) | 2019-12-11 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| WO2021127376A1 (en) | 2019-12-21 | 2021-06-24 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| CN115551836A (zh) * | 2020-05-06 | 2022-12-30 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂的多晶型物 |
| EP4146173A4 (en) * | 2020-05-06 | 2024-05-29 | Corcept Therapeutics Incorporated | FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS |
| CA3202353A1 (en) * | 2020-12-21 | 2022-06-30 | Jeffrey Mark Dener | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022235647A1 (en) * | 2021-05-05 | 2022-11-10 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| CA3243549A1 (en) * | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS |
| EP4598513A1 (en) | 2022-10-06 | 2025-08-13 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| IL320512A (en) | 2022-10-28 | 2025-06-01 | Corcept Therapeutics Inc | Amyotrophic lateral sclerosis treatments using desocorilant |
| WO2024249440A1 (en) * | 2023-05-30 | 2024-12-05 | Corcept Therapeutics Incorporated | Pyrylium method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2024249437A1 (en) * | 2023-05-30 | 2024-12-05 | Corcept Therapeutics Incorporated | Sulfone method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| DE3011809A1 (de) | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
| US5008267A (en) | 1988-10-29 | 1991-04-16 | Mitsui Toatsu Chemicals, Incorporated | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same |
| JPH06128238A (ja) | 1992-10-20 | 1994-05-10 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体 |
| EP0722732A1 (en) | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Long-acting drug formulation containing pyrimidinedione derivatives |
| DE69612698T2 (de) * | 1995-06-09 | 2001-12-06 | F. Hoffmann-La Roche Ag, Basel | Pyrimidindion-, Pyrimidintrion-, Triazindion-Derivate als alpha-1-adrenergische Rezeptorantagonisten |
| JPH1017555A (ja) | 1996-07-02 | 1998-01-20 | Mitsui Petrochem Ind Ltd | ６−アミノ−５−メチルウラシル誘導体 |
| ES2246292T3 (es) | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | Moduladores de receptor glucocorticoide. |
| GB0029100D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
| US20030225075A1 (en) | 2002-04-10 | 2003-12-04 | Orchid Chemicals & Pharmaceuticals Limited | Novel pyrimidone derivatives |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1761497B1 (en) * | 2004-01-09 | 2008-09-03 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| KR101210730B1 (ko) * | 2004-07-02 | 2012-12-10 | 코어셉트 쎄라퓨틱스, 잉크. | 변형된 피리미딘 글루코코티코이드 수용체 조절제 |
| KR101237312B1 (ko) * | 2006-02-10 | 2013-03-04 | 삼진제약주식회사 | 피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물 |
| DE102006033109A1 (de) * | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| SG193509A1 (en) * | 2011-03-18 | 2013-10-30 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
-
2012
- 2012-03-16 SG SG2013069992A patent/SG193509A1/en unknown
- 2012-03-16 CN CN201280023901.1A patent/CN103596431B/zh active Active
- 2012-03-16 JP JP2013558200A patent/JP6039587B2/ja active Active
- 2012-03-16 UA UAA201312083A patent/UA109931C2/ru unknown
- 2012-03-16 BR BR112013023689-2A patent/BR112013023689B1/pt active IP Right Grant
- 2012-03-16 PE PE2013002053A patent/PE20141378A1/es active IP Right Grant
- 2012-03-16 MX MX2013010490A patent/MX347862B/es active IP Right Grant
- 2012-03-16 US US13/422,399 patent/US8685973B2/en active Active
- 2012-03-16 DK DK12760812.3T patent/DK2685827T3/en active
- 2012-03-16 PL PL12760812T patent/PL2685827T3/pl unknown
- 2012-03-16 PH PH1/2013/501906A patent/PH12013501906A1/en unknown
- 2012-03-16 ES ES12760812.3T patent/ES2563444T3/es active Active
- 2012-03-16 CA CA2830411A patent/CA2830411C/en active Active
- 2012-03-16 EP EP12760812.3A patent/EP2685827B1/en active Active
- 2012-03-16 MY MYPI2013003340A patent/MY161170A/en unknown
- 2012-03-16 WO PCT/US2012/029376 patent/WO2012129074A1/en not_active Ceased
- 2012-03-16 AU AU2012231265A patent/AU2012231265B2/en active Active
- 2012-03-16 KR KR1020187011496A patent/KR101925955B1/ko active Active
- 2012-03-16 KR KR1020137027459A patent/KR101889742B1/ko active Active
- 2012-03-16 RU RU2013146518/04A patent/RU2599253C2/ru not_active IP Right Cessation
-
2013
- 2013-09-16 CL CL2013002667A patent/CL2013002667A1/es unknown
- 2013-09-16 IL IL228466A patent/IL228466A/en active IP Right Grant
- 2013-09-27 ZA ZA2013/07245A patent/ZA201307245B/en unknown
- 2013-10-16 CO CO13245606A patent/CO6821943A2/es not_active Application Discontinuation
-
2014
- 2014-02-13 US US14/179,960 patent/US8906917B2/en active Active
- 2014-11-07 US US14/535,719 patent/US9321736B2/en active Active